BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).

Inclusion Criteria:

• 20 years or older
• Japanese male or female
• Non- valvular atrial fibrillation documented by ECG
• Patients aged 60 years and older or with a risk of stroke

Exclusion Criteria:

• Prior stroke and TIA
• Patients in whom anticoagulants are contraindicated